Today's guest is Elizabeth Nolan Brown, whose recent Reason cover story looks into the politics of the Make America Healthy Again (MAHA) movement spearheaded by Health and Human Services Secretary Robert F. Kennedy Jr.

Just a decade or so ago, it was Democrats, liberals, and progressives who were pushing healthy eating initiatives and it was common to see Republicans and conservatives such as Sarah Palin brandish Big Gulps like AR-15s and Fox News anchors such as Sean Hannity declare their loyalty to Kentucky Fried Chicken.

But now the Trumpian right is embracing wellness and food purity like nobody's business—and is using the state to enforce its preferences.

Nick Gillespie talks with Brown about how we got here, where the MAHA movement is headed—and whether you've eaten your last red M&M.

This episode was recorded live in front of an audience in New York City. Go here to get information about upcoming events, including The Reason Roundtable live in New York on July 15!

Subscribe at YouTube: http://youtube.com/reasontv
Like us on Facebook: https://www.facebook.com/Reason.Magazine
Follow us on Twitter: https://twitter.com/reason
Visit the archive: https://reason.com/tags/reason-podcast


From Big Gulps to Raw Milk: The Rise of MAHA

This interview provides a strategic overview for navigating medical device clinical trials, highlighting the fundamental philosophical differences between the US FDA approach and the EU's Medical Device Regulation (MDR). It details how early choices like device classification based on intended use and risk and differing equivalence requirements significantly shape the process, alongside outlining the ongoing post-market data collection and reporting burden in the EU and the critical steps and challenges of trial execution, especially tight safety reporting timelines.

Navigating the Clinical  Trials Gauntlet US FDA vs EU MDR in Medical Device Trials

https://www.hanf-magazin.com/recht/rechtslage-international/rechtliche-grauzone-der-fall-delta-8-in-den-usa/

Die Legalisierung von Hanf in den USA hat einen rechtlichen Graubereich geschaffen, in dem sogenannte intoxicating hemp derivatives wie Delta‑8‑THC oder HHC zunehmend für Verwirrung sorgen. Diese Substanzen werden aus legalem CBD hergestellt, sind psychoaktiv und in vielen Bundesstaaten ohne klare Regulierung erhältlich. Während Hersteller Gesetzeslücken nutzen, warnen Behörden wie die FDA und DEA vor gesundheitlichen Risiken, insbesondere für Jugendliche. Gerichtsurteile widersprechen sich, was zu Rechtsunsicherheit für Produzenten und Konsumenten führt. Der politische Druck steigt: Für die Farm Bill 2025 werden strengere Vorschriften diskutiert, um Konsumentenschutz, Produktkontrolle und Jugendprävention zu gewährleisten. Auch in Europa zeichnet sich eine ähnliche Entwicklung ab, etwa mit HHC-Produkten. Die Debatte zeigt, wie notwendig eine klare rechtliche Linie im Umgang mit neuartigen Hanf-Derivaten ist – für alle Beteiligten.

Rechtliche Grauzone: Der Fall Delta-8 in den USA

Pink Sheet Executive Editor Derrick Gingery, Senior Writer Sarah Karlin-Smith, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs discuss why Center for Biologics Evaluation and Research Director Vinay Prasad cited an unproven theory alleging politics influenced the 2020 COVID-19 vaccine emergency use authorizations to justify his decision to overrule reviewers on more recent indication updates (:35). They also consider the impact of hundreds of staff departures after the US Food and Drug Administration’s reduction-in-force was allowed to proceed, including 600 in the Center for Drug Evaluation and Research (20:14). 

More On These Topics From The Pink Sheet

Prasad Cites Unproven Theory Defending His COVID-19 Vaccine Decisions: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/prasad-cites-unproven-theory-defending-his-covid-19-vaccine-decisions-QFAGD35QOFA5VCZS4WXDPCNWV4/ 

US FDA’s Drugs Center Lost Hundreds Of Staff Through June With 600 RIFs Coming: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/us-fdas-drugs-center-lost-hundreds-of-staff-through-june-with-600-rifs-coming-GYSWOX6RIZEXTK5LZ4KWF3PPDY/ 

Drug Fix: CBER Director’s Political Spin On COVID-19 Vaccines And US FDA RIFs Finalized

Pink Sheet Executive Editor Derrick Gingery, Senior Writer Sarah Karlin-Smith and Editor-in-Chief Nielsen Hobbs discuss the issues awaiting George Tidmarsh, the new director of the US Food and Drug Administration’s Center for Drug Evaluation and Research (:24), as well as the next steps for the agency and Sarepta amid the ongoing problems with its gene therapy Elevidys (delandistrogene moxeparvovec) (23:49).

More On These Topics From The Pink Sheet

Will Tidmarsh’s Industry Experience Translate As US FDA’s Chief Drug Regulator?: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/breaking-news-pharma-ceo-george-tidmarsh-named-director-of-us-fdas-drug-center-2HXJJCPAIVB2RFNGDDU5NZVNQQ/

Business Background Of New CDER Director George Tidmarsh: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/business-background-of-new-cder-director-george-tidmarsh-BROCYQDUYFE3LIQDJ2JNBDWD6Y/ 

US FDA Cancer Reviewers Heading For The Exits, Potentially Impacting Review Timelines: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/us-fda-cancer-reviewers-heading-for-the-exits-potentially-impacting-review-timelines-YMOFTXDFDZBGVGBIKFXHJY5XTY/ 

US FDA’s Biologics Center Departures Grew Before More Than 100 RIFs Exited: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/us-fdas-biologics-center-departures-grew-before-more-than-100-rifs-exited-2LR3ZFYOBND3DLIWXSFFWWLFYE/ 

After Sarepta Reversed Course On Elevidys, Could An Adcomm Be Next?: https://insights.citeline.com/pink-sheet/product-reviews/post-marketing-regulation-and-studies/after-sarepta-reversed-course-on-elevidys-could-an-adcomm-be-next-ZA5ODQB3DJF4LBDFODMB52DM3M/ 

Sarepta Refuses To Stop Elevidys Shipments After Third Death Linked To Gene Therapy Vector: https://insights.citeline.com/pink-sheet/advanced-technologies/cell-and-gene-therapies/us-fda-asks-sarepta-to-stop-elevidys-shipments-after-third-death-linked-to-gene-therapy-vector-GLJ2YJDJGNBPLD3SSKKE6UVM34/ 


Drug Fix: US FDA’s New Top Drug Regulator, Sarepta’s Options After Elevidys Stand-Off

Maxwell's lawyer says DOJ asked her about roughly "100 different people"       
more          China's Struggling Economy: What Happened to the Dream?      
News On he Flipside We been played the whole Epstein is a lie we going prove it tonight also a lot of other news to cover .NASA Is Watching a Huge Anomaly Growing in Earth's Magnetic Field        China’s Groundbreaking Flying Car Could Change Transportation Forever     US-Chinese Citizen Caught Stealing Top-Secret American Missile Technology for China     Why China's Stolen Stealth Fighter is Problematic     Donald Trump and Elon Musk's bizarre bromance just took another unexpected turn      
              A science journal pulled a controversial study about a bizarre life form against the authors' wishes          Trump Wins 6-3 Supreme Court Ruling — Sotomayor Leads Dissent            How the Air Force Debuts a New Jet in Just 3 Minutes      Beloved Mexican Chain Faces FDA Ban on Multiple Menu Items     House ethics panel tells Rep. Alexandria Ocasio-Cortez to pay more for Met Gala attendance          The asteroid that will spare Earth might hit the moon instead. What happens if it does?    Trump administration moves to release billions in federal education cash      Dream Chaser: NASA’s Next-Generation Space Shuttle—Will It Ever Launch?   Here's How The Sixth-Gen F-47 Fighter Jet Got Its Name     Elon Musk Killed Starlink Over Ukraine, Hurting a Counteroffensive Against Russia: Reuters

News On he Flipside We been played the whole Epstein is a lie we going prove it tonight

The use of apoquel for treatment of allergic dermatitis in horses is becoming more common. The product is approved by the Food and Drug Administration.

8/13/25 - Apoquel treatment of allergic dermatitis in horses

твои игры

femboy sigma

Pink Sheet Executive Editor Derrick Gingery, Senior Writer Sarah Karlin-Smith and Senior Editor Sue Sutter discuss the impact of US Food and Drug Administration’s COVID-19 vaccine indication changes and recission of the associated emergency use authorizations, as well as the postmarketing studies that now are required (:40), and their potential impact on access and reimbursement (12:20). 

More On These Topics From The Pink Sheet

COVID-19 Vaccines: Pfizer Arguments To Keep EUA Failed To Persuade US FDA’s Prasad: https://insights.citeline.com/pink-sheet/vaccines/covid-19-vaccines-pfizer-arguments-to-keep-eua-failed-to-persuade-us-fdas-prasad-V3X2OEBZE5HRHKO7KMMCFXBM2Q/ 

US FDA Updates COVID-19 Vaccine Formulations, Revokes EUAs, ACIP Use Decision Next: https://insights.citeline.com/pink-sheet/vaccines/us-fda-updates-covid-19-vaccine-formulations-revokes-euas-acip-use-decision-next-VBXJDSOA6BCOXNCA2TAH27EBJY/ 

A US FDA Move to Revoke Pfizer’s Pediatric COVID-19 Vaccine EUA Could Raise Supply Questions: https://insights.citeline.com/pink-sheet/vaccines/a-us-fda-move-to-revoke-pfizers-pediatric-covid-19-vaccine-eua-could-raise-supply-questions-ZX26DBENHFCOHPBGMPFPQB6REQ/
 
Changes In Pediatric COVID-19 Vaccine Recommendations Causing Coverage Confusion: https://insights.citeline.com/pink-sheet/vaccines/changes-in-pediatric-covid-19-vaccine-recommendations-causing-coverage-confusion-WDEYUVJXGBCGBEVBQ2I6INH554/ 

Drug Fix: US FDA Changes COVID-19 Vaccine Labeling, Reimbursement Confusion Rises

Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.

Founded in 1968, Reason is the planet's leading source of news, politics, and culture from a libertarian perspective. Our podcast offerings include:

The Reason Roundtable
Every Monday, the libertarian editors of the magazine of “Free Minds and Free Markets”—Matt Welch, Nick Gillespie, Katherine Mangu-Ward, and Peter Suderman—discuss and debate the week’s biggest stories and what fresh hell awaits us all.

The Reason Interview with Nick Gillespie
Want to know what comes next in politics, culture, and libertarian ideas? Reason’s Nick Gillespie hosts relentlessly interesting interviews with the activists, artists, authors, entrepreneurs, newsmakers, and politicians who are defining the 21st century.

The Soho Forum Debates
Reason presents a libertarian-themed debate series recorded monthly before a live audience in New York City. Moderated by former Barron's Economics Editor Gene Epstein, the Soho Forum features Nobel prize winners, radical thinkers, and other public intellectuals facing off over the future of bitcoin, veganism, sex work, illegal drugs, electric vehicles, abortion, robotics, government debt, and other controversial topics.

hanf-magazin.com ist das größte deutschsprachige Magazin zum Thema Hanf.

Audio on this website is not authorized for broadcast use without the express written consent of Texas Farm Bureau. You must be a contracted affiliate of the Texas Farm Bureau Radio Network to broadcast our audio.  All content and other intellectual property (“Material”) herein is the property of its respective owners or licensees, which includes Texas Farm Bureau.  Texas Farm Bureau reserves all rights.  Material from this website may not be broadcast or otherwise disseminated without the express written consent of Texas Farm Bureau.

The best variety in News, Sports, Esoteric talk online and over the airwaves on Earth. The new learning channel UPRNtalkradio.com

New tracks tagged #FDA